Manmeet Ahluwalia, MD, MBA, Miami Cancer Institute, discussed efforts being taken by his organization’s Center for Equity in Cancer Care & Research to address disparities in clinical trial enrollment of minority patients in the United States.
The Center for Equity in Cancer Care & Research aims to bridge the significant gap in enrollment of minority patients within clinical trials that lead to FDA approval of oncology drugs, said Manmeet Ahluwalia, MD, MBA, chief, Solid Tumor Medical Oncology, deputy director, and chief scientific officer at Miami Cancer Institute.
Transcript
Can you speak on the community-level health inequities among the populations you serve with Miami Cancer Institute and how these factors have influenced strategies at the new Center for Equity in Cancer Care & Research?
Despite all the advances in cancer care [in the] United States, there is a significant disparity in care of patients who are minority in origin. For example, if you look at clinical trials that lead to FDA approval of drugs in oncology, only 3% to 4% of those patients are African American in origin and only 3% to 4% of those patients are in Hispanic origin. Whereas you look at the United States population, 20% of the United States population is Hispanic origin, and 13% to 14% is African American.
So, when you add these 2, African Americans and Hispanics, although they constitute one-third of the US population, only 5% to 6% of these patients are enrolled in clinical trials. So, a major emphasis of our program is to bolster the minority enrollment in clinical trials. And as a primarily Hispanic-serving institution, we have a major focus in building the trust, and we are doing that through our partners in the community.
We have launched several initiatives where we are taking advantage of community health care workers, and we are working closely with Health Council of South Florida to partner to increase the minority enrollment to clinical trials and bridge this gap of minorities in trials that lead to FDA approval of drugs, which is a major emphasis for the White House, the National Institutes of Health, National Cancer Institute, and the FDA. Miami Cancer Institute is bolstering this initiative with our efforts in South Florida. And to this, we've been lucky to [receive] a generous donation from one of our philanthropic partners who have given us $2 million to organize and operationalize the center, which will be key to driving these efforts locally and then partnering with people nationally.
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More